Related Experiment Video

Updated: Aug 18, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

TAB2 Causes Neuronal Damage by Aggravating Microglia-Mediated Neuroinflammation in Parkinson's Disease

Yanhao Zhao1, Zimeng Huang1, Jianing Gao1

  • 1Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|August 17, 2026
PubMed

Insights

Targeting TAB2 in microglia reduces neuroinflammation and protects neurons in Parkinson's disease models. This pathway involves STAT3, NF-κB, and IL-1β, offering a potential therapeutic strategy for PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Neuroinflammation exacerbates dopaminergic neuron loss in Parkinson's disease (PD).
  • TAB2 was identified as an elevated biomarker in microglia of PD patients.
  • The role of TAB2 in PD pathogenesis was previously unknown.

Purpose of the Study:

  • To investigate the role of TAB2 in the pathogenesis of Parkinson's disease.
  • To elucidate the molecular mechanisms by which TAB2 influences neuroinflammation in PD.
  • To evaluate TAB2 as a potential therapeutic target for PD.

Main Methods:

  • Utilized PD mouse models with Tab2 knockdown (both general and microglia-specific).
  • Investigated the interaction of TAB2 with α-synuclein and its role in signaling pathways (TAK1, NF-κB).
  • Assessed the effects of lumacaftor on microglial TAB2 expression and PD models.

Main Results:

  • Tab2 knockdown inhibited microglia activation and protected dopaminergic neurons in PD models.
  • TAB2 interacts with α-synuclein, facilitating TAK1 and NF-κB pathway activation.
  • Microglia-specific Tab2 knockdown improved motor function and reduced anxiety-like behaviors in PD mice.
  • Lumacaftor suppressed microglial TAB2 expression, demonstrating anti-inflammatory and neuroprotective effects.

Conclusions:

  • The STAT3-TAB2-NF-κB-IL-1β axis in microglia is a critical driver of neuroinflammation in PD.
  • TAB2 plays a pivotal role in regulating microglia-mediated neuroinflammation in Parkinson's disease.
  • Targeting TAB2 presents a potential therapeutic strategy for mitigating PD progression.
Keywords:
TAB2lumacaftorneuroinflammationparkinson's disease

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...